['hypercholesterolemia']
['bococizumab (pf-04950615;rn316)', 'bococizumab (pf-04950615;rn316)', 'bococizumab (pf-04950615;rn316)', 'placebo', 'ezetimibe', 'bococizumab (pf-04950615;rn316)', 'bococizumab (pf-04950615;rn316)', 'bococizumab (pf-04950615;rn316)', 'placebo']

        Inclusion Criteria:

          -  Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population
             A).

          -  Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
             controlled (Population B).

        Exclusion Criteria:

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Pregnant females; breastfeeding females; males and females of childbearing potential;
             males and females of childbearing potential who are unwilling or unable to use a
             highly effective method of contraception.

          -  Subjects who were administered or prior exposed to PF-04950615 and/or anti-body
             targeting PCSK9.
      